Main Catalog

Found 79
Sort By
Nexus 2020 Virtual
Member
Non-Member

Overcoming Barriers to Biosimilar Adoption through Coordinated Efforts

Contact Hours: 1 - Biosimilars are considered a fundamental pillar to containing drug spend in today’s health care systems.
Biosimilars
Nexus 2020 Virtual
Member
Non-Member

Population Management: Zooming in on Rare Diseases with ICER Reports

Contact Hours: 1 - An estimated 10% of the population has a rare disease, according to the National Organization of Rare Disorders (NORD), which lists over 1,200 rare diseases.
ICER
Nexus 2020 Virtual
Member
Non-Member

Specialty Pharmaceuticals in Development Nexus 2020

Contact Hours: 1 - Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs.
Specialty
Nexus 2020 Virtual
Member
Non-Member

The Evolving Role of Managed Care in the Gene Therapy Era: Focus on Hemophilia

Contact Hours: 1 - The first gene therapies for hemophilia A and B are expected to reach the market by 2022, with more projected in the coming years.
Gene Therapy
Nexus 2020 Virtual
Member
Non-Member

The State of Prescription Drug Pricing Reform: Are States Leading the Way for the US?

Contact Hours: 1 - Debates from Washington, D.C. frequently drown out changes happening in state capitals. This is true for drug pricing as well.
Drug Pricing
Nexus 2019
Member Free
Non-Member

The Managed Care Evaluation of Non-Alcoholic Steatohepatitis Treatment Options

Contact Hours: 1.5. Non-alcoholic steatohepatitis (NASH) is a liver disease resulting from metabolic dysfunction that can lead to serious and costly health conditions, such as inflammation, hepatocellular injury, progressive fibrosis, and cirrhosis.
NASH
Nexus 2019
Member Free
Non-Member

Real-Time Pharmacy Benefits: Results and Learnings from a Real-World Implementation

Contact Hours: 1.5. Real-time pharmacy benefits (RTPB) deliver real-time access to medication pricing and restriction information at the point of prescribing.
Real-TIme Pharmacy
Nexus 2019
Member Free
Non-Member

Checking In on Health Care Reform Efforts: What Do They Mean for Payers, Manufacturers, and Patients?

Contact Hours: 1.5. While broader drug pricing reform efforts have taken the lion’s share of attention in health policy discourse over the past year, the Trump Administration has continued to move forward with implementing changes to the Affordable Care Act (ACA).
Health Care Reform
Nexus 2019
Member Free
Non-Member

Innovative Value-Based Contracting Approaches with Comprehensive Clinical Strategies

Contact Hours: 1.5. Innovative approaches to developing value-based contracts in the market need to be multi-faceted.
Value-Based Contracting
Nexus 2019
Member Free
Non-Member

Releasing Format Version 4.1: Updates, Perspectives and Application

Contact Hours: 1.5. The Academy of Managed Care Pharmacy developed the AMCP Format for Formulary Submission
Format 4.1